Biolinerx Ltd. cash flow statement

In fiscal 2025, Biolinerx Ltd.'s operations generated −$8.1m of cash; it spent $25,000 on capital projects, leaving free cash flow of −$8.1m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Biolinerx Ltd.: cash flow statement, annual
Fiscal year	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash from operations	−24	−26	−23	−44	−8
Depreciation and amortisation	1	1	1	0	0
Stock-based pay	1	2	2	1	0
Capital spending	0	0	0	0	0
Free cash flow	−24	−26	−23	−44	−8
Free cash flow after stock pay	−25	−29	−25	−45	−8

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: BLRX vs LGVN BLRX vs DARE BLRX vs STTK

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Biolinerx Ltd.'s SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Biolinerx Ltd.